Published in Cancer Biother Radiopharm on June 15, 2013
Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol (2013) 0.90
Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial. Medicine (Baltimore) (2016) 0.78
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer (2016) 0.77
Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis. PLoS One (2016) 0.77
Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol (2016) 0.75
Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials. Am Health Drug Benefits (2016) 0.75
Targeted pharmacotherapy after somatic cancer mutation screening. F1000Res (2016) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med (1998) 19.07
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials (2007) 14.51
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med (1999) 9.40
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Colorectal cancer. Lancet (2005) 4.90
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol (2001) 4.89
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol (2010) 4.81
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol (2005) 4.32
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol (2005) 3.79
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol (2006) 3.70
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol (2008) 3.66
Aggregate data meta-analysis with time-to-event outcomes. Stat Med (2002) 3.63
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet (2000) 3.27
Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med (2002) 3.16
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst (2005) 2.74
Chemotherapy for colorectal cancer. N Engl J Med (1994) 2.67
Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology (2010) 2.62
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol (2012) 2.59
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol (2009) 2.34
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol (2004) 2.24
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol (2010) 2.23
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol (2011) 2.02
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med (2007) 1.83
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol (2009) 1.71
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol (2001) 1.58
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 1.41
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist (2007) 1.38
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer (2011) 1.32
A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis (2009) 1.20
Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer (1996) 1.10
CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol (1996) 0.88
Optimizing the efficacy of first-line chemotherapy plus bevacizumab in metastatic colorectal cancer: analysis of multiple methods. BioDrugs (2011) 0.86
Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer. Cancer Treat Rev (2004) 0.77
Expression profile of osteoblast lineage at defined stages of differentiation. J Biol Chem (2005) 1.83
Reduced opioid consumption and improved early rehabilitation with local and intraarticular cocktail analgesic injection in total hip arthroplasty: a randomized controlled clinical trial. Pain Med (2011) 1.47
Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res (2007) 1.33
Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev (2007) 1.14
A novel PRPF31 splice-site mutation in a Chinese family with autosomal dominant retinitis pigmentosa. Mol Vis (2004) 1.11
MST1 promotes apoptosis through phosphorylation of histone H2AX. J Biol Chem (2010) 1.07
Extracellular signal-regulated kinase 8-mediated c-Jun phosphorylation increases tumorigenesis of human colon cancer. Cancer Res (2010) 1.00
Efficacy of intra-articular cocktail analgesic injection in total knee arthroplasty - a randomized controlled trial. Knee (2009) 0.96
Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis. Cancer Res (2009) 0.93
Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at Ser63 and Ser73 enhances cell transformation. Cancer Res (2009) 0.91
Sodium chloride modified silica nanoparticles as a non-viral vector with a high efficiency of DNA transfer into cells. Curr Gene Ther (2003) 0.90
Arthroscopic single-bundle posterior cruciate ligament reconstruction: retrospective review of hamstring tendon graft versus LARS artificial ligament. Int Orthop (2008) 0.90
Phosphorylation of H2AX at Ser139 and a new phosphorylation site Ser16 by RSK2 decreases H2AX ubiquitination and inhibits cell transformation. Cancer Res (2011) 0.89
Expression, purification, and characterization of human and rat acetyl coenzyme A carboxylase (ACC) isozymes. Protein Expr Purif (2006) 0.89
Co-culture with mesenchymal stem cells enhances metabolic functions of liver cells in bioartificial liver system. Biotechnol Bioeng (2012) 0.89
Transumbilical single-incision laparoscopic distal pancreatectomy: primary experience and review of the English literature. World J Surg (2014) 0.85
The preliminary experimental and clinical study of the relationship between the pigment gallstone and intestinal mucosal barrier. J Gastroenterol Hepatol (2009) 0.85
Phosphorylation of histone H2B serine 32 is linked to cell transformation. J Biol Chem (2011) 0.85
Structural diversity of the active N-terminal kinase domain of p90 ribosomal S6 kinase 2. PLoS One (2009) 0.84
Effect of perioperative parecoxib on postoperative pain and local inflammation factors PGE2 and IL-6 for total knee arthroplasty: a randomized, double-blind, placebo-controlled study. Eur J Orthop Surg Traumatol (2013) 0.81
A novel locus for autosomal dominant nonsyndromic hearing loss identified at 5q31.1-32 in a Chinese pedigree. J Hum Genet (2002) 0.80
Changes of hemoglobin and hematocrit in elderly patients receiving lower joint arthroplasty without allogeneic blood transfusion. Chin Med J (Engl) (2015) 0.78
PDGFR-β-activated ACK1-AKT signaling promotes glioma tumorigenesis. Int J Cancer (2014) 0.77
LPS stimulates MUC5AC expression in human biliary epithelial cells: whether there exists a possible pathway of PKC/NADPH/ROS? Mol Cell Biochem (2013) 0.77
Transumbilical single-incision laparoscopic distal pancreatectomy: preliminary experience and comparison to conventional multi-port laparoscopic surgery. BMC Surg (2014) 0.76
Lack of efficacy of prophylactic application of antibiotic-loaded bone cement for prevention of infection in primary total knee arthroplasty: results of a meta-analysis. Surg Infect (Larchmt) (2015) 0.76
[Translational frameshift may be occur in p11, an interaction protein of Cx31, in yeast]. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) (2002) 0.76
[Silica nanoparticles modified as carriers for gene transfection]. Yi Chuan Xue Bao (2003) 0.75
[A mutation IVS2+1G>A in EXT2 gene causes hereditary multiple exostoses]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2004) 0.75
[Effect of hormone replacement therapy on homocysteine and echocardiography in postmenopausal women]. Zhonghua Fu Chan Ke Za Zhi (2002) 0.75
[Genetic diagnosis and prenatal genetic diagnosis of fragile X syndrome]. Yi Chuan (2003) 0.75
[Expression and purification of p11 fusion protein in E. coli and preparation of antiserum against GST-p11]. Hunan Yi Ke Da Xue Xue Bao (2002) 0.75
[Splicing site mutation of D19S418 in PRPF-31 gene and its phenotypic characters with autosomal dominant retinitis pigmentosa]. Zhonghua Yan Ke Za Zhi (2005) 0.75
Transumbilical single-incision laparoscopic combined cholecystectomy and appendectomy: a retrospective comparative study. J Laparoendosc Adv Surg Tech A (2014) 0.75
[A simple and convenient method for construction of gene site-directed mutagenesis]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2002) 0.75
Single-incision laparoscopic versus traditional multiport laparoscopic colorectal surgery--a cumulative meta-analysis and systematic review. Int J Colorectal Dis (2013) 0.75
Single-incision laparoscopic biliary bypass for malignant obstructive jaundice. J Gastrointest Surg (2015) 0.75
[Expression of c-terminal of Parkin in E. coli and the preparation of antiserum]. Hunan Yi Ke Da Xue Xue Bao (2002) 0.75
[Familial and genetic study in a large Chinese kindred with hereditary nonpolyposis colorectal cancer]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2007) 0.75
[Effectiveness comparison of two arthroscopic different fixations for anterior cruciate ligament tibial eminence avulsion fractures]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2011) 0.75
Sphincter of Oddi manometry by choledochoscope in patients with duodenobiliary reflux. J Gastroenterol Hepatol (2011) 0.75
[CONDITIONS OF SYNOVIAL MESENCHYMAL STEM CELLS DIFFERENTIATING INTO FIBROCARTILAGE CELLS]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2015) 0.75
[Separation of adhering cell colonies with a direct digestion method]. Hunan Yi Ke Da Xue Xue Bao (2002) 0.75
[Exclusive gene mapping on retinitis pigmentosa with markers on chromosomes 3 in a Chinese kindred]. Zhonghua Yan Ke Za Zhi (2003) 0.75
[PERIOPERATIVE BLOOD MANAGEMENT STRATEGIES FOR JOINT ARTHROPLASTY]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2015) 0.75
Photovoltaic absorber with different grating profiles in the near-infrared region. J Opt Soc Am A Opt Image Sci Vis (2017) 0.75
[Construction of middle fragment deletion mutant with improved gene splicing by overlap extension]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2004) 0.75